Ultragenyx Sells Additional 25% Crysvita Royalty Interest to OMERS for $400 Million
Ultragenyx Pharmaceutical Inc. has announced the sale of an additional 25% of its royalty interest in future North American sales of Crysvita® (burosumab) to OMERS Life Sciences for $400 million. This non-dilutive financing agreement will provide Ultragenyx with immediate capital to support four anticipated product launches and strengthen its balance sheet. Under the new agreement, OMERS will begin receiving the additional 25% royalty interest on net sales of Crysvita in the U.S. and Canada starting in January 2028. The total payments to OMERS under this and the previous 2022 agreement are capped at 1.55 times the purchase price. OMERS will continue to receive 30% of Crysvita net sales in North America following the achievement of the 2022 agreement's cap.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568671-en) on November 04, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。